InQubeta and Injective poised for gains

Disclosure: This article does not represent investment advice. The content and materials featured on this page are for educational purposes only.

Bitcoin (BTC) recently broke above the $43,000 mark, rising to the highest level this year. This surge in price can be attributed to various factors, including a peak in yearly inflows totaling $1.5 billion and anticipation surrounding the upcoming halving event in April 2024. 

Additionally, there is speculation about the approval of a spot Bitcoin ETF by the Securities and Exchange Commission (SEC) in the first week of 2024; further lifting prices.

InQubeta (QUBE) and Injective (INJ) are notable cryptos due to their decentralized finance services. InQubeta aims to simplify investor access to AI investments. Launching on Ethereum, it utilizes smart contracts and fractionalization to provide an alternative for investing in artificial intelligence (AI).

Injective offers various services, including lending protocols and decentralized exchanges (DEXes). INJ is already up 917% this year. 

Looking at InQubeta

InQubeta aims to offer an alternative to traditional investment options, providing investors with easier access to investment opportunities. The project delivers a mutually beneficial ecosystem for AI startups seeking capital and investors looking to invest in new ventures. 

InQubeta focuses on AI and has a crowdfunding approach that directs funds to firms advancing AI. The investment process works by startups creating ERC-20 tokens that represent investment opportunities. These tokens are similar to the decentralized version of stocks. 

Investors can purchase NFTs using QUBE from the marketplace, hold them long-term, or resell them. InQubeta investors can earn profits by holding QUBE or staking to help operate the blockchain. 

A small supply of QUBE and deflationary taxes may support prices. QUBE is available for $0.01925 in the ongoing presale. 

Since AI is growing exponentially, InQubeta supporters are bullish on QUBE’s prospects. Over $1.5 trillion could pour into the industry in the coming years, and InQubeta might benefit.

Injective rose by 917% in 2023

Injective is a platform for hosting decentralized finance (defi) services. Its users can access various solutions, including prediction markets and derivatives exchanges. 

The infrastructure is compatible with other major blockchains like Ethereum and Solana

Since 2023, INJ prices have been rising and could extend gains in the years ahead. 

The solutions provided by Injective to the unbanked and those who prefer defi put it in a position for exponential growth as crypto adoption rises.


QUBE and INJ are being explored due to their growth potential. QUBE supporters expect more gains before the end of the presale and even after launching. Meanwhile, there are odds of INJ extending gains, rising in sync with Bitcoin.

Visit InQubeta presale 

Join the InQubeta communities

Disclosure: This content is provided by a third party. does not endorse any product mentioned on this page. Users must do their own research before taking any actions related to the company.

Follow Us on Google News


No comments yet. Why don’t you start the discussion?

Leave a Reply

Your email address will not be published. Required fields are marked *